Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Comment by Mackinnon80on Jan 14, 2016 3:17pm
200 Views
Post# 24459221

RE:RE:article

RE:RE:articleYou have to understand the signification of a "narrow indication". Every oncologic drug on the market have a limited label. Meaning they are limited to a specific (or limited) population.

If the FDA approves a label that includes 60 % of the initial targeted population by the sponsor, will you call it a double-narrowed of a narrower indication ? My point is...the word "narrowed" is irrelevant here. You get an approval for a specific population. Bottom line.

At worst, TST will get an approval for a population of several thousands of patients (on-label). Which is not bad at all compared to a lot of other oncologic drugs label.

M80
<< Previous
Bullboard Posts
Next >>